The total number of trials is greater than the total number of studies (n = 37) because 1 study24 included 2 trials (ie, 2 cognitive behavioral therapy for insomnia [CBT-I] conditions, each with an independent control/comparison condition).
Variation in data marker size indicates relative weighting by sample size. CBT-I indicates cognitive behavioral therapy for insomnia; COPD, chronic obstructive pulmonary disease; ISI, Insomnia Severity Index; PD, Parkinson disease; PSQI, Pittsburgh Sleep Quality Index; and PTSD, posttraumatic stress disorder.
All outcomes were derived from sleep diaries. Variation in data marker size indicates relative weighting by sample size. CBT-I indicates cognitive behavioral therapy for insomnia; COPD, chronic obstructive pulmonary disease; PD, Parkinson disease; PLMD, periodic limb movement disorder; and PTSD, posttraumatic stress disorder.
Variation in data marker size indicates relative weighting by sample size. BDI indicates Beck Depression Inventory; CBT-I, cognitive behavioral therapy for insomnia; COPD, chronic obstructive pulmonary disease; CPS, Chronic Pain Scale; FSS, Fatigue Severity Scale; HRSD, Hamilton Rating Scale for Depression; MFSI-SF, Multidimensional Fatigue Inventory–Short Form; MPQ, McGill Pain Questionnaire; OSA, obstructive sleep apnea; PCL-M, PTSD Checklist–Military Version; PFS, Piper Fatigue Scale; PHQ-9, Patient Health Questionnaire; PLMD, periodic limb movement disorder; POMS-SF, POMS–Short-Form; and PTSD, posttraumatic stress disorder.
eTable 1. Summary of CBT-I Components
eTable 2. Study Quality Ratings Summary
eFigure. Sleep Quality Controlled Effect Sizes From Baseline to Posttreatment
Customize your JAMA Network experience by selecting one or more topics from the list below.
Wu JQ, Appleman ER, Salazar RD, Ong JC. Cognitive Behavioral Therapy for Insomnia Comorbid With Psychiatric and Medical Conditions: A Meta-analysis. JAMA Intern Med. 2015;175(9):1461–1472. doi:10.1001/jamainternmed.2015.3006
Cognitive behavioral therapy for insomnia (CBT-I) is the most prominent nonpharmacologic treatment for insomnia disorders. Although meta-analyses have examined primary insomnia, less is known about the comparative efficacy of CBT-I on comorbid insomnia.
To examine the efficacy of CBT-I for insomnia comorbid with psychiatric and/or medical conditions for (1) remission from insomnia; (2) self-reported sleep efficiency, sleep onset latency, wake after sleep onset, total sleep time, and subjective sleep quality; and (3) comorbid symptoms.
A systematic search was conducted on June 2, 2014, through PubMed, PsycINFO, the Cochrane Library, and manual searches. Search terms included (1) CBT-I or CBT or cognitive behavioral [and its variations] or behavioral therapy [and its variations] or behavioral sleep medicine or stimulus control or sleep restriction or relaxation therapy or relaxation training or progressive muscle relaxation or paradoxical intention; and (2) insomnia or sleep disturbance.
Studies were included if they were randomized clinical trials with at least one CBT-I arm and had an adult population meeting diagnostic criteria for insomnia as well as a concomitant condition. Inclusion in final analyses (37 studies) was based on consensus between 3 authors’ independent screenings.
Data Extraction and Synthesis
Data were independently extracted by 2 authors and pooled using a random-effects model. Study quality was independently evaluated by 2 authors using the Cochrane risk of bias assessment tool.
Main Outcomes and Measures
A priori main outcomes (ie, clinical sleep and comorbid outcomes) were derived from sleep diary and other self-report measures.
At posttreatment evaluation, 36.0% of patients who received CBT-I were in remission from insomnia compared with 16.9% of those in control or comparison conditions (pooled odds ratio, 3.28; 95% CI, 2.30-4.68; P < .001). Pretreatment and posttreatment controlled effect sizes were medium to large for most sleep parameters (sleep efficiency: Hedges g = 0.91 [95% CI, 0.74 to 1.08]; sleep onset latency: Hedges g = 0.80 [95% CI, 0.60 to 1.00]; wake after sleep onset: Hedges g = 0.68; sleep quality: Hedges g = 0.84; all P < .001), except total sleep time. Comorbid outcomes yielded a small effect size (Hedges g = 0.39 [95% CI, 0.60-0.98]; P < .001); improvements were greater in psychiatric than in medical populations (Hedges g = 0.20 [95% CI, 0.09-0.30]; χ2 test for interaction = 12.30; P < .001).
Conclusions and Relevance
Cognitive behavioral therapy for insomnia is efficacious for improving insomnia symptoms and sleep parameters for patients with comorbid insomnia. A small to medium positive effect was found across comorbid outcomes, with larger effects on psychiatric conditions compared with medical conditions. Large-scale studies with more rigorous designs to reduce detection and performance bias are needed to improve the quality of the evidence.
Cognitive behavioral therapy for insomnia (CBT-I) is a multicomponent treatment package that usually includes stimulus control, sleep restriction, and cognitive therapy (eTable 1 in the Supplement) and has emerged as the most prominent nonpharmacologic treatment for chronic insomnia.1,2 Previous meta-analyses have found that CBT-I improves sleep parameters and sleep quality at post treatment3-8 and follow-up6 for adults and older adults.5 Most of these studies selected individuals with primary insomnia, excluding patients with comorbid psychiatric and medical conditions. However, patients with insomnia who present to internists and primary care physicians are likely to report comorbid conditions associated with the sleep disturbance. Furthermore, insomnia was previously conceptualized as a symptom arising from the comorbid disorder and treatment was targeted at the underlying disorder. However, accumulating evidence9,10 indicates that insomnia can have a distinct and independent trajectory from the comorbid disorder, thus indicating a need for separate treatment from the comorbid condition.
As a result of this paradigm shift, the literature on CBT-I for comorbid insomnia has flourished over the past decade. Randomized clinical trials have examined the efficacy of CBT-I on a range of comorbidities including cancer, chronic pain, depression, and posttraumatic stress disorder. Although reviews11,12 have been conducted on CBT-I and comorbid psychiatric conditions, to our knowledge no meta-analysis has examined the effect of CBT-I on both psychiatric and medical conditions. Given the patient profile encountered in primary care and internal medicine, data on remission and treatment effects of CBT-I for comorbid insomnia could aid in treatment planning and referrals.
The purpose of this meta-analysis was to answer 2 research questions regarding the efficacy of CBT-I for comorbid insomnia populations: What is the efficacy of CBT-I on sleep outcomes and insomnia symptoms for comorbid insomnia? What is the efficacy of CBT-I on outcomes related to the comorbid condition? Given the heterogeneity in comorbid conditions and study design, exploratory analyses were conducted to examine potential moderators of treatment effects.
A systematic search was conducted June 2, 2014, in PubMed, PsycINFO, and the Cochrane Library from the first available date. The following sets of search terms were used: (1) CBT-I or CBT or cognitive behavioral [and its variations] or behavioral therapy [and its variations] or behavioral sleep medicine or stimulus control or sleep restriction or relaxation therapy or relaxation training or progressive muscle relaxation or paradoxical intention; and (2) insomnia or sleep disturbance. In addition, manual searches were conducted through reference lists of reviews and meta-analyses identified through the above systematic database searches.
From the pool of studies identified by the database searches, published studies were selected if they met the inclusion criteria. First, the trial had CBT-I as a treatment arm, defined as a multicomponent intervention that includes at least one behavioral component plus a cognitive or relaxation therapy (eTable 1 in the Supplement), which is consistent with the standard recommendations for the treatment of insomnia disorders.2 Second, the sample consisted of adults 18 years or older who met Diagnostic and Statistical Manual of Mental Disorders (Third Edition), Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition), or International Statistical Classification of Diseases and Related Health Problems, Tenth Revision criteria for an insomnia disorder or established quantitative criteria for insomnia, and another well-characterized psychiatric disorder (ie, primary symptoms are mental) or medical condition (ie, primary symptoms are physical). Third, the trial had a randomized controlled design including at least one control or comparison group that did not receive CBT-I. Finally, the trial reported sufficient data for performing effect size (ES) calculations for primary variables of interest. Studies were excluded if the data reported in the trial represented a secondary analysis or were reported in another included trial, if the data were unpublished, or if an English version of the article was not available.
The selection process was conducted by 3 of us (J.Q.W., E.R.A., and R.D.S.), during which each of the studies identified as relevant through the initial search was independently evaluated for inclusion and exclusion criteria by at least 2 of 3 authors. Initial interrater agreement was 94%. All disagreements regarding a trial’s eligibility were resolved through case-by-case discussion among raters.
Remission from insomnia was derived from 2 standard measures that are recommended as global measures of insomnia.13 The Insomnia Severity Index (ISI) is a brief 7-item scale with a total score of less than 8 serving as a cut-off value for insomnia remission.14 The Pittsburgh Sleep Quality Index (PSQI) is a 10-item scale with a total score of 5 or less serving as a cut-off for “good sleepers.”15
Sleep parameters included sleep diary measures of sleep efficiency (SE), total sleep time (TST), sleep onset latency (SOL), and wake after sleep onset (WASO), as well as self-report measures of subjective sleep quality. These variables were chosen because they are clinically meaningful in the assessment of insomnia severity13 and were the most commonly reported outcomes among included studies.
Main outcomes identified in each study for the specified comorbid disorder were extracted as the comorbid outcome measure for the present meta-analysis. In cases in which disorder-specific outcomes (eg, kidney functioning) were not measured or reported, general outcomes of fatigue, depression, anxiety, and quality of life were substituted as comorbid outcomes.
A priori analyses were designed to produce (1) posttreatment remission rates and odds ratios (ORs); (2) baseline to posttreatment controlled treatment ESs for sleep and comorbid outcomes; (3) baseline to follow-up controlled treatment ESs for sleep outcomes and comorbid outcomes; and (4) moderating effects of type of comorbidity, length of treatment, publication year, sample size, and objective vs subjective measurements of sleep parameters on ESs.
Two of us (J.Q.W., R.D.S.) identified target outcomes from each included trial and extracted numeric data. In the case of multiple control/comparison conditions, the most active nonpharmacologic condition was chosen. If an appropriate nonpharmacologic condition did not exist, the pharmacologic condition was chosen. Twenty-five percent of extracted data were independently entered by those 2 of us to spot-check for accuracy. If data necessary for effect size or remission rate calculations were not reported in the published article, corresponding authors were contacted with data requests, and the trial was excluded from analyses if the authors were unable to provide necessary data or did not respond after 3 contact attempts.
A random-effects model was used to account for variance in design and outcome variables.16,17 To compare rates of remission from insomnia between groups, we calculated pooled ORs. To evaluate the effects of CBT-I on sleep and comorbid symptoms, we calculated the pooled Hedges g value and its 95% CI. Consistent with convention, a conservative estimate of r = 0.70 was used as the pre-post correlation in the calculation if it was not reported.18 Consistent with convention, an effect size of 0.2 was interpreted as small, 0.5 as medium, and 0.8 as large.19 In trials with multiple measures of outcome variables (eg, PSQI and ISI), ES estimates were averaged across all measures. To explore the potential role of type of comorbidity and objective vs subjective measures of sleep parameters as moderators of treatment effects, we conducted separate subgroup analyses. Furthermore, we entered publication year, sample size, and treatment length into a metaregression model to evaluate their potential relative contributions to between-study variance.
Several strategies were used to address potential publication bias: (1) conducting fail-safe N analyses18,20 to assess the robustness of ESs; (2) inspecting funnel plots to assess overrepresentation of positive and negative studies; and (3) using the trim-and-fill method to adjust ESs accordingly.21 Study quality was assessed independently by 2 of us (J.Q.W. and J.C.O.) using the Cochrane Collaboration’s risk of bias assessment tool.22 In each domain, studies were given a rating of low risk, high risk, or unclear risk. Consensus ratings were reached through discussion between these 2 of us. All analyses were performed using the software program Comprehensive Meta-Analysis, version 2.23
The initial database and manual search identified 1683 nonunique hits that yielded 158 potential studies for further examination (Figure 1). Of these, 68 qualified for preliminary inclusion, but 21 were excluded because they were duplicates or reported secondary analyses of data already reported in another included trial. A further 10 studies could not be included because their full-text articles could not be obtained or the published article did not report adequate data needed for meta-analysis, and authors were unable to provide them. One other study was excluded because it did not report sleep diary or comorbid outcomes. Thus, the present meta-analysis extracted data from 36 published studies. Because one study24 included multiple intervention and control conditions that allowed for analyses of 2 independent CBT-I interventions, each with an appropriate control condition, the final analyses reflect ESs from 37 randomized clinical trials.
Characteristics of analyzed trials are presented in the Table. They were published between 1996 and 2014. The 37 trials reported data from a total of 2189 participants. There was a range of comorbid disorders falling into 3 broad categories: psychiatric (n = 10)25-34 medical (n = 26),24,35-58 and mixed (n = 1).9 The mean total sample size per trial was 59.16. Most trials included both male and female participants, with the exception of 8 trials that included only women with breast cancer or fibromyalgia.37,40-42,48-50,56 Trials used a range of control or comparison groups, including waiting list control or delayed treatment or symptom monitoring (10), treatment as usual (7), sleep hygiene education (7), and other active behavioral comparison conditions (13), such as behavioral placebo treatment, pharmacotherapy, mindfulness-based stress reduction, surgery, and relaxation training. Twenty-six trials24-37,42,45-48,50,51,53-58 used the ISI and/or PSQI, and of these, only 4 failed to provide data on remission.34,36,50,54 The most common assessment methods for the quantitative sleep parameters were sleep diaries/logs and, for subjective sleep quality, the PSQI and ISI (Table). Ten trials reported SE, SOL and WASO as measured by actigraphy or polysomnography, which did not produce sufficient objective sleep data for quantitative synthesis.
Overall, the quality of studies was moderate to high, and we judged them to have generally low risk of bias in most domains (eTable 2 in the Supplement). High risk in performance bias (42.1%) and detection bias (57.9%) were observed. The potential for bias in these domains was the result of having a waiting list or treatment as usual control condition and unblinded participants, therapists, and assessors. Overall, only 3 studies9,42,53 received a high-risk rating in more than 2 domains.
Twenty-two trials24-33,35,37,45,47,51-53,55-58 reported or provided ISI or PSQI at post treatment, allowing calculation of remission rates based on a total of 482 control patients and 539 patients who underwent CBT-I (Figure 2). Of patients receiving CBT-I, 36.0% reached remission status, compared with 16.9% of those in control/comparison conditions. Meta-analysis yielded a pooled OR of 3.28 (95% CI, 2.30-4.68; P < .001). The fail-safe N was a robust 280. The funnel plot of log OR and standard error was asymmetrical toward the right, indicating potential publication bias. The newly imputed OR was 2.61.
Twenty-four trials9,24-29,31,32,35,36,38-40,43,46,47,49,52,54-57 reported SE using sleep diaries (Figure 3). The random effects meta-analysis yielded a pooled Hedges g = 0.91 (95% CI, 0.74 to 1.08; z = 10.32; P < .001). With an α level of .01, the fail-safe N for the SE analysis was 1028 (z = 12.98), indicating that 1028 trials with ESs of zero would be needed to nullify these results. The above pooled ES is thus considered statistically robust. The funnel plot revealed potential publication bias; the trim-and-fill analysis21 determined that 1 trial would have to fall to the right of the mean to render the plot symmetrical, and the newly imputed ES after adjusting for asymmetry was Hedges g = 0.93 (95% CI, 0.76-1.10).
Twenty trials reported SOL,9,25-27,29-32,35,36,39-41,43,44,46,47,49,52,54-57 yielding a pooled Hedges g = 0.80 (95% CI, 0.60 to 1.00; z = 7.79, P < .001). The fail-safe N was a statistically robust 614 (z = 11.03). Trim and fill analysis21 indicated no publication bias.
Eighteen trials9,25-27,29,31,32,35,39,40,42-44,46,47,52,54,55,57 reported WASO, yielding a pooled Hedges g = 0.68 (95% CI, 0.60-0.98; z = 8.08; P < .001), with a statistically robust fail-safe N of 333 (z = 11.22). The funnel plot was symmetrical, indicating no publication bias.
Twenty-five trials9,24-32,35,36,38-41,43-47,49,52,54-57 reported TST, with a pooled Hedges g = 0.19 (95% CI, 0.06-0.31; z = 2.92; P = .003). However, the fail-safe N of 55 (z = 3.50) was less than 5k +10, where k is the number of observed trials; the above pooled ES is not considered statistically robust. Therefore, TST was excluded from further moderator analyses.
Thirty-four trials9,24-37,39,40,42,43,45-58 reported on subjective sleep quality (eFigure in the Supplement), yielding a pooled Hedges g = 0.84 (95% CI, 0.69-1.00; z = 10.42; P < .001), with a statistically robust fail-safe N of 2206 (z = 15.91). Trim and fill analysis21 indicated no publication bias.
Thirty-one trials9,24-26,28-39,42-52,55,57,58 reported clinical outcomes for the target comorbid disorder using psychometrically validated self-report instruments and standard medical outcome measures (Figure 4), yielding a pooled Hedges g = 0.39 (95% CI, 0.25-0.53; z = 5.51; P < .001). The fail-safe N for the sleep quality analysis was a statistically robust 409 (z = 7.38). Trim and fill analysis21 determined that 13 trials would have to fall to the left of the mean to render the plot symmetrical, indicating potential publication bias; the newly imputed ES after adjusting for asymmetry was Hedges g = 0.16 (95% CI, 0.01-0.32).
Thirteen trials9,26,27,33-35,39,41,43,45,48,49,54 reported follow-up outcomes for both CBT-I and control/comparison groups, with follow-up time points ranging from 3 to 12 months post intervention. Of these, only 8 trials9,26,27,35,39,43,49,54 reported SE outcomes at follow-up to yield a medium ES (Hedges g = 0.61; 95% CI, 0.39-0.82; z = 5.61; P < .001, fail-safe N = 58; z = 7.42). Adjusted Hedges g was 0.52 (95% CI, 0.33-0.72) with trim-and-fill analysis.21 Twelve trials9,26,27,33-35,39,43,45,48,49,54 reported sleep quality at follow-up outcomes to yield a medium to large ES (Hedges g = 0.70; 95% CI, 0.25-0.52; z = 5.61; P < .001, fail-safe N = 161; z = 7.42). Trim-and-fill analysis21 indicated an adjusted Hedges g = 0.55, 95% CI [0.30 to 0.81]. Follow-up outcomes were reported in 10 trials for TST,9,26,27,35,39,41,43,45,49,54 8 for SOL,9,26,27,34,35,39,43,54 and 7 for WASO.9,27,35,39,42,43,54 There was not enough power to produce statistically robust pooled ESs (fail-safe N values <36) for these outcomes.
Nine studies of insomnia comorbid with psychiatric disorders25,26,28-34 (Hedges g = 0.76; 95% CI, 0.46-1.05) yielded a larger pooled ES on comorbid outcomes than did 21 studies of insomnia comorbid with medical conditions24,35-39,42-52,55,57,58 (Hedges g = 0.20; 95% CI, 0.09-0.30; χ2 test for interaction = 12.30; P < .001), suggesting that psychiatric symptoms comorbid with insomnia may be more responsive to CBT-I than are medical symptoms. However, there were no significant differences between the 2 types of comorbid populations in terms of sleep outcomes (χ2 test for interactions <1.32; all P > .31). In other words, the positive response to CBT-I on insomnia symptoms does not appear to be moderated by the type of comorbid condition.
Ten trials27,28,31,39-41,43,44,47,54 reported actigraphy and/or polysomnography measures of SE, SOL, and/or WASO. Owing to a lack of power, statistically robust pooled ESs could not be produced (ie, fail-safe N values ≤29). Preliminary findings indicated statistically nonsignificant ESs in the small to medium range for SE (n = 10; Hedges g = 0.12; 95% CI, −0.30 to 0.27; P = .12), SOL (n = 7; Hedges g = 0.46, 95% CI, 0.18 to 0.74; P = .01), and WASO (n = 8; Hedges g = 0.53; 95% CI, 0.07 to 1.00; P = .02).
With an α level of .01, omnibus tests did not reach statistical significance (Q < 8.953; P > .03); together, publication year, sample size, and treatment length contributed 9% or less of the between-study variance to sleep and comorbid outcomes. However, holding other covariates constant, increase in the number of sessions predicted slightly larger improvement in sleep quality (β = 0.13; z = 2.62; P < .01). Publication year and sample size did not independently predict sleep/comorbid parameter ESs (|β|s <.02, all P > .29).
The present meta-analysis examined the efficacy of CBT-I across 37 randomized clinical trials that included 2189 patients with insomnia comorbid with psychiatric and medical conditions. Overall, our findings indicate that CBT-I has positive effects on reducing insomnia symptoms and sleep disturbances in comorbid insomnia. At posttreatment evaluation, 35.6% of the patients who received CBT-I were in remission from insomnia, compared with 17.4% of those in control or comparison conditions. Pre-post controlled ESs were medium to large for most sleep parameters, including improvements in SE and subjective sleep quality and reductions in SOL and WASO, with the range from Hedges g being 0.67 to 0.88. These ESs are similar to those found in meta-analyses of primary insomnia trials6-8 and collectively support the efficacy of CBT-I in reducing insomnia symptoms and improving sleep parameters across primary and comorbid insomnia disorders. In addition, the treatment effects remained in the medium range for SE and sleep quality at follow-up, indicating that the benefits of CBT-I are generally maintained 3 to 12 months after completing treatment. Consistent with one previous review,6 CBT-I did not yield significant effects on TST at posttreatment evaluation.
Cognitive and behavioral therapy for insomnia also had positive effects on comorbid outcomes, including condition-specific clinical indices and general measures of mood and functioning, yielding a small to medium pooled ES of Hedges g = 0.39. The extent of improvement in comorbid symptoms was moderated by the type of comorbidity such that patients with psychiatric disorders demonstrated significantly larger changes (Hedges g = 0.76) compared with those with medical conditions (Hedges g = 0.20). There were no significant differences between the 2 populations in terms of improvements on sleep indices. These findings indicate that CBT-I has positive effects on sleep across comorbid conditions, but it has stronger effects on comorbid symptoms in psychiatric conditions compared with comorbid symptoms in medical conditions, leading to 2 possible hypotheses. First, sleep disturbance may be more strongly associated with cognitive-emotional symptoms than with physical symptoms. Therefore, reducing sleep disturbance would have a stronger effect on psychiatric illness, especially given the inclusion of sleep disturbance among the symptoms of posttraumatic stress disorder and mood disorders, 2 common psychiatric comorbidities. Second, greater improvements in psychiatric symptoms may be due to common factors, which have been hypothesized to account for a proportion of the variance across different forms of psychotherapy.59 For example, it is possible that patients with comorbid psychiatric symptoms benefit globally from elements of cognitive therapy contained in CBT-I, which have been shown to be effective for anxiety,60 depression,61 and quality of life in general.62
The trials reviewed in the present meta-analysis were of generally good quality and had low risk of bias. Approximately 90% of the trials were found to have a high risk for bias in 2 domains or fewer. However, we found large discrepancies on detection and performance bias. Specifically, few trials described efforts to use blinded assessors to collect self-report data or to score objective measures (polysomnography or actigraphy). Although self-reported sleep logs and global measures of insomnia severity are considered standard assessments for insomnia,13,63 methods for collecting and scoring these data to minimize potential bias have not been specified. Mobilizing resources to reduce detection and performance bias in future randomized clinical trials on insomnia disorders could improve the methodologic rigor of this literature. In addition, the mean sample size of the studies was only 59 participants, indicating that the trials reviewed were mostly small-scale pilot studies. Overall, the literature on comorbid insomnia is still maturing and more rigorous, large-scale studies are needed to yield more stable and consistent effect sizes.
Several limitations should be noted with regards to our findings. First, there were only 10 trials that reported objective measures of sleep and rest-activity at both pretreatment and posttreatment (Table). As a result, independent ESs for each method could not be meaningfully produced; thus, the effects of CBT-I on objective measures of sleep remain inconclusive. Second, there were insufficient studies reporting TST at follow-up to examine the long-term effect of CBT-I on TST. Third, the full range of psychiatric and medical conditions is not represented in these studies, and the outcome measures on the comorbid condition were heterogeneous. In some studies, the outcome was specific to the comorbid condition, such as the percentage of abstinent days in the context of substance dependence25; in other studies, the outcome was a sequela of the comorbid condition or treatment of the comorbid condition, such as fatigue in the context of breast cancer.37,49,52 As a result, we were unable to specify the direction of the association between insomnia and the comorbid condition.
Our findings indicate that CBT-I can improve insomnia symptoms and sleep parameters when insomnia is comorbid with medical and psychiatric conditions. Furthermore, CBT-I can affect symptoms associated with the comorbid condition, with stronger effects observed in psychiatric conditions compared with medical conditions. These findings provide empirical support for the recommendation of using CBT-I as the treatment of choice for comorbid insomnia disorders.1,2 Given that insomnia disorders are highly prevalent in primary care settings,64,65 health care professionals in these settings should regularly assess for sleep disturbances in the context of comorbid conditions and efforts should be directed at adapting CBT-I to the time constraints in this setting. For example, a brief behavioral therapy for insomnia delivered by a trained nurse has demonstrated efficacy in primary care66 and can serve as a model for implementing CBT-I in this setting.
Accepted for Publication: April 6, 2015.
Corresponding Author: Jason C. Ong, PhD, Sleep Disorders Service and Research Center, Department of Behavioral Sciences, Rush University Medical Center, 1653 W Congress Pkwy, Chicago, IL 60612 (firstname.lastname@example.org).
Published Online: July 6, 2015. doi:10.1001/jamainternmed.2015.3006.
Author Contributions: Ms Wu and Dr Ong had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Wu.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Wu, Ong.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Wu.
Administrative, technical, or material support: Wu, Appleman, Salazar, Ong.
Study supervision: Ong.
Conflict of Interest Disclosures: Dr Ong serves as a consultant to Sleepio, Inc. This activity is not related to the present study. No other conflicts are reported.